AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3

Trivoglicad 1mg/500mg/0.3mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Cadomed Pharmaceuticals Pvt Ltd

Salt Composition

Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)

Overview Trivoglicad 1mg/500mg/0.3mg Tablet ER

Glycadia-Trio 1mg/500mg/0.3mg Extended-Release Tablets are classified as antidiabetic medications. This combination therapy manages type 2 diabetes in adults by regulating blood glucose. Glycadia-Trio 1mg/500mg/0.3mg ER should be ingested with food, consistently at the same time daily for optimal efficacy. Dosage is determined and adjusted by your physician based on your blood sugar response. Continued use is crucial, even with controlled blood sugar, as discontinuation without medical consultation risks elevated glucose levels, potentially leading to kidney complications, vision loss, neuropathy, and limb amputation. Remember, this medication complements a comprehensive diabetes management plan including diet, exercise, and weight management as directed by your doctor. Lifestyle choices significantly impact diabetes control. Hypoglycemia (low blood sugar) is a common side effect; learn to recognize symptoms like sweating, dizziness, headache, and tremors, and carry a rapid-acting glucose source (e.g., sugary foods, juice). Alcohol consumption elevates hypoglycemia risk and should be limited. Other potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, edema, blurred vision, bone fractures, and upper respiratory infections. Weight gain may occur. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Inform your doctor of any heart history prior to use, as it may be unsuitable. Pregnant or lactating individuals should seek medical advice before commencing treatment. Regular blood glucose monitoring, along with blood cell and liver function tests as advised by your physician, is essential.

Uses of Trivoglicad 1mg/500mg/0.3mg Tablet ER

Managing type 2 diabetes

Major Benefits of Trivoglicad 1mg/500mg/0.3mg Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Trivoglicad 1mg/500mg/0.3mg Extended-Release tablet whole; avoid crushing, chewing, or breaking it. Administer on an empty stomach.

Common Side effects of Trivoglicad 1mg/500mg/0.3mg Tablet ER:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Hypoglycemia (low blood glucose level)
  • Loss of appetite

How to use Trivoglicad 1mg/500mg/0.3mg Tablet ER:

Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the entire Trivoglicad 1mg/500mg/0.3mg Extended-Release tablet without chewing, crushing, or breaking it. Administer on an empty stomach.

How Trivoglicad 1mg/500mg/0.3mg Tablet ER works:

Extended-release Triglicad tablets (1mg/500mg/0.3mg) contain a triple-action formulation for diabetes management.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent alcohol use with Trivoglicad 1mg/500mg/0.3mg Extended-Release tablets is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Trivoglicad tablets (1mg/500mg/0.3mg) may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential advantages against any possible risks prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Trivoglicad tablets (1mg/500mg/0.3mg) are likely unsafe for breastfeeding mothers. Available human data indicate potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyUNSAFE

Patients with kidney disease should likely avoid Trivoglicad 1mg/500mg/0.3mg Tablet ER due to potential safety concerns. Medical advice is recommended. The use of Trivoglicad 1mg/500mg/0.3mg Tablet ER is contraindicated in individuals with severe kidney impairment.

LiverLiverCAUTION

Patients with liver impairment should use Trivoglicad 1mg/500mg/0.3mg Extended-Release tablets cautiously, potentially requiring dosage modification. Consult a physician. Individuals with mild to moderate hepatic dysfunction typically begin on a low dose; however, Trivoglicad 1mg/500mg/0.3mg Extended-Release tablets are contraindicated in those with severe liver disease.

What if you forget to take Trivoglicad 1mg/500mg/0.3mg Tablet ER :

Should you forget to take your Trivoglicad 1mg/500mg/0.3mg Extended-Release tablet, administer it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Trivoglicad 1mg/500mg/0.3mg Tablet ER

LabelValue
Developing Habits No.
Type of Therapy Diabetes Management

FAQs on Trivoglicad 1mg/500mg/0.3mg Tablet ER

Trivoglicad 1mg/500mg/0.3mg Extended-Release Tablets combine glimepiride, metformin, and voglibose to manage type 2 diabetes mellitus in adults. This combination improves blood glucose control when used with diet and exercise. Glimepiride stimulates insulin release, metformin reduces liver glucose production and enhances insulin sensitivity, and voglibose, an alpha-glucosidase inhibitor, lowers post-meal glucose levels. Trivoglicad is not suitable for type 1 diabetes.
Trovoglicad 1mg/500mg/0.3mg Extended-Release tablets may cause common side effects including hypoglycemia, nausea, diarrhea, taste changes, flatulence, abdominal pain, headache, rash, and respiratory infections.
Trovoglicad 1mg/500mg/0.3mg Tablet ER is contraindicated in patients allergic to its components or excipients, those with moderate to severe kidney disease, and those with inflammatory bowel disease, colonic ulcerations, or underlying metabolic acidosis, including diabetic ketoacidosis.
Combining Trivoglicad 1mg/500mg/0.3mg ER tablets with alcohol is unsafe. This combination can worsen hypoglycemia and raise the risk of lactic acidosis.
Trovoglicad 1mg/500mg/0.3mg Tablet ER can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other antidiabetic medications. Regular blood sugar monitoring is crucial. Always carry a readily available source of glucose, such as glucose tablets, honey, or fruit juice.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it remains inaccessible to children, pets, and others.
Trivoglicad 1mg/500mg/0.3...
91
MRP 111
17% off